Enzon Pharmaceuticals Inc (ENZN)
0.0949
+0.01
(+7.11%)
USD |
OTCM |
May 17, 16:00
Enzon Pharmaceuticals Enterprise Value: -38.94M for May 17, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 17, 2024 | -38.94M |
| May 16, 2024 | -39.41M |
| May 15, 2024 | -39.31M |
| May 14, 2024 | -39.31M |
| May 13, 2024 | -39.68M |
| May 10, 2024 | -39.55M |
| May 09, 2024 | -39.31M |
| May 08, 2024 | -39.68M |
| May 07, 2024 | -39.87M |
| May 06, 2024 | -40.16M |
| May 03, 2024 | -40.42M |
| May 02, 2024 | -40.42M |
| May 01, 2024 | -39.69M |
| April 30, 2024 | -39.79M |
| April 29, 2024 | -39.79M |
| April 26, 2024 | -39.79M |
| April 25, 2024 | -39.46M |
| April 24, 2024 | -40.20M |
| April 23, 2024 | -40.20M |
| April 22, 2024 | -40.62M |
| April 19, 2024 | -40.62M |
| April 18, 2024 | -40.62M |
| April 17, 2024 | -40.62M |
| April 16, 2024 | -41.18M |
| April 15, 2024 | -40.44M |
| Date | Value |
|---|---|
| April 12, 2024 | -38.95M |
| April 11, 2024 | -38.95M |
| April 10, 2024 | -38.95M |
| April 09, 2024 | -39.13M |
| April 08, 2024 | -40.07M |
| April 05, 2024 | -40.79M |
| April 04, 2024 | -40.79M |
| April 03, 2024 | -41.16M |
| April 02, 2024 | -41.39M |
| April 01, 2024 | -40.18M |
| March 28, 2024 | -40.00M |
| March 27, 2024 | -40.00M |
| March 26, 2024 | -40.74M |
| March 25, 2024 | -41.67M |
| March 22, 2024 | -41.82M |
| March 21, 2024 | -41.07M |
| March 20, 2024 | -41.82M |
| March 19, 2024 | -42.56M |
| March 18, 2024 | -40.87M |
| March 15, 2024 | -40.87M |
| March 14, 2024 | -40.87M |
| March 13, 2024 | -40.81M |
| March 12, 2024 | -40.70M |
| March 11, 2024 | -41.82M |
| March 08, 2024 | -41.82M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-42.56M
Minimum
Mar 19 2024
15.47M
Maximum
Dec 29 2020
-15.30M
Average
-21.20M
Median
Oct 13 2021
Enterprise Value Benchmarks
| AIM ImmunoTech Inc | 7.729M |
| Perspective Therapeutics Inc | 817.27M |
| Protalix BioTherapeutics Inc | 55.51M |
| Electromed Inc | 130.07M |
| Armata Pharmaceuticals Inc | 187.82M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 0.32M |
| Total Expenses (Quarterly) | 0.326M |
| EPS Diluted (Quarterly) | -0.0028 |
| Earnings Yield | 1.01% |
| Normalized Earnings Yield | -22.21 |